10-KPeriod: FY2000

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2000

Filed April 2, 2001For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) is positioning itself as the nation's leading provider of diagnostic testing and related services, boasting approximately $3.4 billion in annual net revenues for the year 2000. The company emphasizes its extensive national network of laboratories and patient service centers, which it believes provides a significant competitive advantage over rivals. A major strategic development highlighted is the August 1999 acquisition of SmithKline Beecham Clinical Laboratories (SBCL), which is expected to drive an annual earnings growth rate exceeding 30% over the coming years, before special charges. Integration of SBCL is largely complete, with expected full integration by 2003 and projected annual synergies of $150 million. The company's business strategy focuses on capitalizing on its market leadership, becoming a leading provider of medical information through its extensive database, emphasizing service quality via Six Sigma initiatives, and driving innovation in new testing technologies, particularly in genomics and molecular diagnostics. Quest Diagnostics also sees significant growth opportunities in strategic areas like selective regional acquisitions, direct-to-consumer testing, higher-margin anatomic pathology services, and expanded offerings for the pharmaceutical and biotechnology industries.

Key Highlights

  • 1Quest Diagnostics holds the leading market share in clinical laboratory testing, with annual net revenues of approximately $3.4 billion, significantly outpacing its nearest competitor.
  • 2The company has completed the integration of the SmithKline Beecham Clinical Laboratories (SBCL) acquisition, which is expected to generate substantial annual earnings growth and $150 million in synergies.
  • 3Quest Diagnostics operates an extensive national network of laboratories, rapid response labs, and patient service centers, providing a broad geographic reach and service capability.
  • 4The company is actively pursuing innovation, particularly in esoteric testing, molecular diagnostics, and genomics, positioning itself for future growth driven by advancements in healthcare.
  • 5Quest Diagnostics is leveraging its vast clinical laboratory database through its Quest Informatics division to offer valuable medical information products to healthcare providers and pharmaceutical companies.
  • 6Strategic growth opportunities include selective regional acquisitions, expansion into the direct-to-consumer testing market, and enhanced services for the pharmaceutical and biotechnology sectors.

Frequently Asked Questions

Quest Diagnostics is the leading provider of diagnostic testing and related services in the United States, with approximately $3.4 billion in annual net revenues. They hold the leading market share in clinical laboratory testing, esoteric testing, anatomic pathology, and drug abuse testing, distinguished by their extensive national network of laboratories and patient service centers.

The acquisition of SBCL, completed in August 1999, is a key strategic move expected to drive annual earnings growth above 30% over the next few years. The integration process is substantially complete, and the company anticipates realizing approximately $150 million in annual synergies from this acquisition.

Quest Diagnostics is focused on several strategic growth areas: capitalizing on its market leadership, expanding its medical information services through its Quest Informatics division, driving innovation in areas like genomics and molecular diagnostics, pursuing selective regional acquisitions, exploring direct-to-consumer testing opportunities, and enhancing services for the pharmaceutical and biotechnology industries.

The company emphasizes quality through initiatives like Six Sigma and has achieved ISO-9001 and ISO-9002 certifications for several of its laboratories. They participate in rigorous external proficiency testing and accreditation programs, such as those from the College of American Pathologists (CAP). Quest Diagnostics is also subject to extensive federal and state regulations, including CLIA, which govern clinical laboratory operations, and is focused on maintaining compliance with evolving privacy regulations like HIPAA.